canada clinical guidance

Abnormal liver blood tests (LFTs): structured primary care approach

A Canadian clinical summary of abnormal liver blood tests (lfts): structured primary care approach, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Practice Guidelines: Evaluation of abnormal liver enzyme tests. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CAG liver tests

Source-attributed clinical priorities

  • Interpret the hepatocellular, cholestatic or isolated bilirubin pattern and compare with prior results and clinical context.
  • Review alcohol, medicines, metabolic risk, viral exposure and autoimmune or inherited clues and order targeted testing.
  • Escalate jaundice with systemic illness, coagulopathy, encephalopathy or marked acute injury and refer persistent unexplained abnormalities.
  • Interpret the pattern and magnitude of abnormality rather than responding to each analyte in isolation.
sources for this section:CAG liver tests

Practical assessment and management workflow

1
Repeat or confirm tests when appropriate and compare alanine aminotransferase, alkaline phosphatase, bilirubin, INR and albumin.
2
Review alcohol, metabolic risk, viral exposure, medicines, supplements and autoimmune or inherited clues.
3
Order targeted serology and ultrasound according to hepatocellular, cholestatic or bilirubin pattern.
4
Calculate fibrosis risk where relevant and refer persistent, unexplained or high-risk disease.
sources for this section:CAG liver tests

Safety, red flags and urgent escalation

  • Encephalopathy, coagulopathy, hypoglycemia or rapidly rising jaundice needs emergency hepatology care.
  • Stop a likely hepatotoxic agent urgently when severe drug-induced liver injury is suspected and seek advice.
  • Do not interpret a normal aminotransferase as excluding advanced chronic liver disease.
sources for this section:CAG liver tests

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CAG liver tests

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CAG liver tests

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Association of GastroenterologyPractice Guidelines: Evaluation of abnormal liver enzyme testsaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.